{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-005263","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2025-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.640481+00:00","generated_at":"2026-05-27T19:59:05.238673+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InMed granted first PCT patent in Mexico for novel cannabinoid analog compounds","bullets":["Patent No. 417531 issued in Mexico; covers novel small molecule compounds and methods of preparation.","Therapeutic applications include pain, glaucoma, inflammatory disease, anxiety, and neurological conditions like Parkinson's and Alzheimer's.","Patent holds 20-year term; international application pending in U.S., Europe, Japan, and others.","InMed now has 14 patent families covering compositions, formulations, manufacturing, and methods of use.","Compounds are drug candidates for Alzheimer's disease and dry age-related macular degeneration programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-005263","json":"https://secwatch.observer/filing/0001213900-25-005263.json","markdown":"https://secwatch.observer/filing/0001213900-25-005263.md","text":"https://secwatch.observer/filing/0001213900-25-005263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025005263/0001213900-25-005263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025005263/ea0228337-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T19:59:05.238673+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}